Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132819 | 1.00 | SLC7A5 (0.57) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| SCHEMBL21994433 | 1.00 | SLC7A5 (0.57) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| SCHEMBL9862545 | 0.87 | SLC7A5 (0.57) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| SCHEMBL9862549 | 0.87 | SLC7A5 (0.57) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| SCHEMBL12104026 | 0.87 | PNMT (0.45) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| SCHEMBL12167696 | 0.87 | PPARG (0.43) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| SCHEMBL30510315 | 0.87 | SLC7A5 (0.57) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL27477387 | 0.86 | SLC7A5 (0.55) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL27478678 | 0.86 | SLC7A5 (0.55) | SLC7A5PTGS1ALOX15HIF1AKDM4E | |
| SCHEMBL1613644 | 0.85 | SLC7A5 (0.62) | SLC7A5PTGS1ALOX15HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113481228-B | Microbial unnatural amino acid introducing system and construction method | 中国药科大学 | 2024-07-19 | — | — | CN | claimed |
| CN-113481228-A | Microorganism unnatural amino acid introduction system and construction method | 中国药科大学 | 2021-10-08 | — | — | CN | claimed |
| CN-113481228-B | Microbial unnatural amino acid introducing system and construction method | 中国药科大学 | 2024-07-19 | — | — | CN | disclosed |
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| CN-113481228-A | Microorganism unnatural amino acid introduction system and construction method | 中国药科大学 | 2021-10-08 | — | — | CN | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| CN-106999536-B | Macrocyclic inhibitors of PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions | 百时美施贵宝公司 | 2020-11-27 | — | — | CN | disclosed |
| WO-2020110008-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | SLC7A5 3361/4885PTGS1 3677/4885ALOX15 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.